Skip to main content
SpringerLink
Log in

The Role of New TKIs and Combinations with Interferon-α for the Treatment of CML

  • Chapter
Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia

  • 712 Accesses

Abstract

Despite the remarkable success of tyrosine kinase inhibitors (TKIs) in the treatment of CML, patients that do not respond or do not tolerate well these agents accumulate, and new options have to be found to avoid these situations. In this chapter, we discuss the importance of ponatinib, a third-generation TKI, and omacetaxine mepesuccinate, an untargeted therapy for such patients, and the use of combinations of TKI and interferon-α front line in order to prevent the onset of disease resistance.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26(20):3358–63.

    Article  PubMed  Google Scholar 

  2. Deininger M, O’Brien SG, Guilhot F. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood. 2009;114(22):1126.

    Google Scholar 

  3. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367(22):2075–88.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783–96.

    Article  CAS  PubMed  Google Scholar 

  5. Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood. 2012;119(6):1501–10.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Talpaz M, McCredie KB, Mavligit GM, Gutterman JU. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood. 1983;62(3):689–92.

    CAS  PubMed  Google Scholar 

  7. Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood. 2001;98(10):3074–81.

    Article  CAS  PubMed  Google Scholar 

  8. Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O’Brien S, et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood. 2007;110(12):4005–11.

    Article  CAS  PubMed  Google Scholar 

  9. Nicolini FE, Corm S, Le QH, Sorel N, Hayette S, Bories D, et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(j)-LMC group). Leukemia. 2006;20(6):1061–6.

    Article  CAS  PubMed  Google Scholar 

  10. Nicolini FE, Ibrahim AR, Soverini S, Martinelli G, Muller MC, Hochhaus A, et al. The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica. 2013;98(10):1510–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006;12(24):7374–9.

    Article  CAS  PubMed  Google Scholar 

  12. Nicolini FE, Basak GW, Soverini S, Martinelli G, Mauro MJ, Muller MC, et al. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood. 2011;118(20):5697–700.

    Article  CAS  PubMed  Google Scholar 

  13. Nicolini FE, Corm S, Le QH, Roche-Lestienne C, Preudhomme C. The prognosis impact of BCR-ABL P-loop mutations: worse or not worse? Leukemia. 2007;21(2):193–4.

    Article  CAS  PubMed  Google Scholar 

  14. Cortes JE, Kim DW, Pinilla-Ibarz J, Le Coutre P, Paquette R, Chuah C, et al. Long-term follow-up of ponatinib efficacy and safety in the Phase 2 PACE Trial. Blood. 2014;124(21): Abstract 3135.

    Google Scholar 

  15. Nicolini FE, Gagnieu MC, Heiblig M, Blond E, Legros L, Guillermin Y. Cardio-vascular events occurring on ponatinib In chronic phase Chronic Myeloid Leukemia patients, preliminary analysis of a multicenter cohort. Blood. 2013;122(21): Abstract 4020.

    Google Scholar 

  16. Corm S, Roche L, Micol JB, Coiteux V, Bossard N, Nicolini FE, et al. Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study. Blood. 2011;118(16):4331–7.

    Article  CAS  PubMed  Google Scholar 

  17. O’Brien S, Kantarjian H, Keating M, Beran M, Koller C, Robertson LE, et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood. 1995;86(9):3322–6.

    PubMed  Google Scholar 

  18. Kantarjian HM, Talpaz M, Santini V, Murgo A, Cheson B, O’Brien SM. Homoharringtonine: history, current research, and future direction. Cancer. 2001;92(6):1591–605.

    Article  CAS  PubMed  Google Scholar 

  19. Cortes J, Digumarti R, Parikh PM, Wetzler M, Lipton JH, Hochhaus A, et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. Am J Hematol. 2013;88(5):350–4.

    Article  CAS  PubMed  Google Scholar 

  20. Nicolini FE, Chomel JC, Roy L, Legros L, Chabane K, Ducastelle S, et al. The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge. Clin Lymphoma Myeloma Leuk. 2010;10(5):394–9.

    Article  CAS  PubMed  Google Scholar 

  21. Legros L, Hayette S, Nicolini FE, Raynaud S, Chabane K, Magaud JP, et al. BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge? Leukemia. 2007;21(10):2204–6.

    Article  CAS  PubMed  Google Scholar 

  22. O’Brien S, Talpaz M, Cortes J, Shan J, Giles FJ, Faderl S, et al. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer. 2002;94(7):2024–32.

    Article  PubMed  Google Scholar 

  23. Burton C, Ranger A, Nadal E. Semi-synthetic homoharringtonine (MyelostatVR) for chronic myeloid leukemia in accelerated phase after imatinib failure. Blood. 2003;102(908): Abstract.

    Google Scholar 

  24. Marin D, Kaeda JS, Andreasson C, Saunders SM, Bua M, Olavarria E, et al. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer. 2005;103(9):1850–5.

    Article  CAS  PubMed  Google Scholar 

  25. O’Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, et al. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer. 2003;98(5):888–93.

    Article  PubMed  Google Scholar 

  26. Cortes JE, Nicolini FE, Wetzler M, Lipton JH, Akard L, Craig A, et al. Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib. Clin Lymphoma Myeloma Leuk. 2013;13(5):584–91.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Nicolini FE, Khoury HJ, Akard L, Rea D, Kantarjian H, Baccarani M, et al. Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors. Haematologica. 2013;98(7):78–9.

    Article  Google Scholar 

  28. de Lavallade H, Khorashad JS, Davis HP, Milojkovic D, Kaeda JS, Goldman JM, et al. Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation. Blood. 2007;110(7):2779–80.

    Article  PubMed  Google Scholar 

  29. Coude MM, Luycx O, Cariou ME, Maarek O, Dombret H, Cayuela JM, et al. Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutation. Br J Haematol. 2012;157(3):407–10.

    Article  CAS  PubMed  Google Scholar 

  30. Cortes J, Lipton JH, Rea D, Digumarti R, Chuah C, Nanda N, et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood. 2012;120(13):2573–80.

    Article  CAS  PubMed  Google Scholar 

  31. Khoury HJ, Cortes J, Baccarani M, Wetzler M, Masszi T, Digumarti R, et al. Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors. Leuk Lymphoma. 2015;56(1):120–7.

    Article  CAS  PubMed  Google Scholar 

  32. Nicolini FE, Hayette S, Legros L, Rousselot P, Maloisel F, Tulliez M, et al. Pegylated IFN-alpha2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone. Leuk Res. 2011;35(1):80–6.

    Article  CAS  PubMed  Google Scholar 

  33. Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010;363(26):2511–21.

    Article  CAS  PubMed  Google Scholar 

  34. Baccarani M, Martinelli G, Rosti G, Trabacchi E, Testoni N, Bassi S, et al. Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. Blood. 2004;104(13):4245–51.

    Article  CAS  PubMed  Google Scholar 

  35. Simonsson B, Gedde-Dahl T, Markevarn B, Remes K, Stentoft J, Almqvist A, et al. Combination of pegylated IFN-alpha2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood. 2011;118(12):3228–35.

    Article  CAS  PubMed  Google Scholar 

  36. Palandri F, Iacobucci I, Castagnetti F, Testoni N, Poerio A, Amabile M, et al. Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome. Haematologica. 2008;93(5):770–4.

    Article  CAS  PubMed  Google Scholar 

  37. Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12(9):841–51.

    Article  CAS  PubMed  Google Scholar 

  38. Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119(5):1123–9.

    Article  CAS  PubMed  Google Scholar 

  39. Cross NC, White HE, Muller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012;26(10):2172–5.

    Article  CAS  PubMed  Google Scholar 

  40. Nicolini FE, Etienne G, Dubruille V, Roy L, Huguet F, Legros L, et al. Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study. Lancet Haematol. 2015;2(1):37–46.

    Article  Google Scholar 

  41. O’Brien S, Kantarjian H, Koller C, Feldman E, Beran M, Andreeff M, et al. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood. 1999;93(12):4149–53.

    PubMed  Google Scholar 

  42. Kantarjian HM, Talpaz M, Smith TL, Cortes J, Giles FJ, Rios MB, et al. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J Clin Oncol. 2000;18(20):3513–21.

    CAS  PubMed  Google Scholar 

  43. Rea D, Nicolini FE, Tulliez M, Rousselot P, Guilhot F, Gardembas M, et al. Dasatinib or nilotinib discontinuation in chronic phase (CP)-Chronic Myeloid Leukemia (CML) patients (pts) with durably undetectable BCR-ABL transcripts: Interim analysis of the STOP 2G-TKI study with a minimum follow-up of 12 months – on behalf of the French CML Group Filmc. Blood. 2014;124(21): Abstract 811.

    Google Scholar 

Download references

Acknowledgments

FEN thanks Barbara White-Meunier, for proofreading this book chapter and the association “Regarde un jour le monde” for their constant support.

Author information

Authors and Affiliations

  1. Hematology Department 1G, Centre Hospitalier Lyon Sud, Lyon, France

    Franck E. Nicolini MD, PhD, Marie Balsat, Hélène Labussière-Wallet, Mohamad Sobh, Arthur Bert & Maël Heiblig

  2. INSERM U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France

    Franck E. Nicolini MD, PhD

  3. French group of CML (Fi-LMC Group), Laboratory of Hematology, Hôpital Haut Lévêque, Pessac, France

    Franck E. Nicolini MD, PhD

Authors
  1. Franck E. Nicolini MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marie Balsat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hélène Labussière-Wallet
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mohamad Sobh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Arthur Bert
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maël Heiblig
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Franck E. Nicolini MD, PhD .

Editor information

Editors and Affiliations

  1. Department of Hematology, Saitama Medical Center Saitama MEdical University, Kawagoe, Saitama, Japan

    Masahiro Kizaki

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Japan

About this chapter

Cite this chapter

Nicolini, F.E., Balsat, M., Labussière-Wallet, H., Sobh, M., Bert, A., Heiblig, M. (2016). The Role of New TKIs and Combinations with Interferon-α for the Treatment of CML. In: Kizaki, M. (eds) Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia. Springer, Tokyo. https://doi.org/10.1007/978-4-431-55714-2_9

Download citation

  • DOI: https://doi.org/10.1007/978-4-431-55714-2_9

  • Publisher Name: Springer, Tokyo

  • Print ISBN: 978-4-431-55713-5

  • Online ISBN: 978-4-431-55714-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation